Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05481359 · ClinicalTrials.gov registry record
AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation
A clinical trial of Atrial Fibrillation and Heart Diseases, sponsored by Ablacon.
- Completed
- Registry status
- 25
- Enrollment target
- 5
- Study locations
NCT05481359: Completed study of Atrial Fibrillation and Heart Diseases, sponsored by Ablacon.
NCT05481359 is a study of Atrial Fibrillation and Heart Diseases that has completed, run by Ablacon. The registered enrollment target is 25 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05481359, a study of Atrial Fibrillation and Heart Diseases, has completed, sponsored by Ablacon.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.
Primary Outcome
Acute Procedure Success is defined as targeting and successful elimination of significant sources of electrographic flow (EGF) through radiofrequency ablation. EGF-identified sources are significant when their leading source activity is ≥ 26%. Successful elimination is defined as reduction of the source activity of the leading source to \<26% upon post-ablation remapping using EGF mapping.
Conditions Studied
Interventions
- DEVICE Electrographic Flow™ (EGF) mapping and ablation
Study Locations (5)
Georgia
- Piedmont Healthcare - Athens
- Piedmont Atlanta Hospital - Atlanta
New York
- Mount Sinai Hospital - New York
South Holland
- Erasmus MC - Rotterdam
Other
- Medicover Hospital - Warsaw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2023-11-17 |
What the finished NCT05481359 record still lists
NCT05481359 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Electrographic Flow™ (EGF) mapping and ablation is the first listed.
NCT05481359 lists 5 locations in 4 states (Georgia, New York, South Holland).
Frequently Asked Questions
What is clinical trial NCT05481359 about?
NCT05481359 is a clinical study titled "AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation". This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.
What is the current status of trial NCT05481359?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2022-09-12. Estimated completion is 2023-11-17.
What conditions does trial NCT05481359 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Heart Diseases, Arrhythmias, Cardiac, Atrial Fibrillation, Persistent.
What interventions are being tested in trial NCT05481359?
The interventions under investigation include: Electrographic Flow™ (EGF) mapping and ablation (DEVICE).
Who is sponsoring clinical trial NCT05481359?
This trial is sponsored by Ablacon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05481359 being conducted?
This trial has 5 study locations across Georgia, New York, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05481359's enrollment target sits among peer trials
25 189th of 202 higher than 13 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI